Marker Therapeutics Inc. (NASDAQ:MRKR) went down by -8.85% from its latest closing price compared to the recent 1-year high of $3.77. The company’s stock price has collected -4.63% of loss in the last five trading sessions. Press Release reported on 03/22/21 that Thinking about buying stock in Acer Therapeutics, Cemtrex, Comstock Mining, Marker Therapeutics, or Strongbridge Biopharma?
Is It Worth Investing in Marker Therapeutics Inc. (NASDAQ :MRKR) Right Now?
Plus, the 36-month beta value for MRKR is at 1.24. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for Marker Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.50. MRKR currently public float of 33.67M and currently shorts hold a 10.37% ratio of that float. Today, the average trading volume of MRKR was 3.35M shares.
MRKR’s Market Performance
MRKR stocks went down by -4.63% for the week, with a monthly drop of -12.34% and a quarterly performance of 19.08%, while its annual performance rate touched 9.57%. The volatility ratio for the week stands at 7.26% while the volatility levels for the past 30 days are set at 10.37% for Marker Therapeutics Inc.. The simple moving average for the period of the last 20 days is -9.11% for MRKR stocks with a simple moving average of 8.80% for the last 200 days.
Analysts’ Opinion of MRKR
Many brokerage firms have already submitted their reports for MRKR stocks, with Piper Sandler repeating the rating for MRKR by listing it as a “Overweight.” The predicted price for MRKR in the upcoming period, according to Piper Sandler is $6 based on the research report published on March 25th of the current year 2021.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see MRKR reach a price target of $6. The rating they have provided for MRKR stocks is “Overweight” according to the report published on March 19th, 2021.
Piper Sandler gave a rating of “Neutral” to MRKR, setting the target price at $2.50 in the report published on May 12th of the previous year.
MRKR Trading at -13.79% from the 50-Day Moving Average
After a stumble in the market that brought MRKR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.36% of loss for the given period.
Volatility was left at 10.37%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares sank -17.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.98% upper at present.
During the last 5 trading sessions, MRKR fell by -4.63%, which changed the moving average for the period of 200-days by unch in comparison to the 20-day moving average, which settled at $2.24. In addition, Marker Therapeutics Inc. saw 42.07% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at MRKR starting from Walker Paul Edward, who purchase 5,714,285 shares at the price of $1.75 back on Mar 16. After this action, Walker Paul Edward now owns 10,714,285 shares of Marker Therapeutics Inc., valued at $9,999,999 using the latest closing price.
SANDELL SCOTT D, the 10% Owner of Marker Therapeutics Inc., purchase 5,714,285 shares at $1.75 during a trade that took place back on Mar 16, which means that SANDELL SCOTT D is holding 10,714,285 shares at $9,999,999 based on the most recent closing price.
Stock Fundamentals for MRKR
Current profitability levels for the company are sitting at:
- -6188.25 for the present operating margin
The net margin for Marker Therapeutics Inc. stands at -6149.74. The total capital return value is set at -68.63, while invested capital returns managed to touch -68.69. Equity return is now at value -87.00, with -61.90 for asset returns.
Based on Marker Therapeutics Inc. (MRKR), the company’s capital structure generated 44.83 points at debt to equity in total, while total debt to capital is 30.95. Total debt to assets is 26.87, with long-term debt to equity ratio resting at 43.40. Finally, the long-term debt to capital ratio is 29.97.
When we switch over and look at the enterprise to sales, we see a ratio of 126.64, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 0.88 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.81.